Reboxetine

DRUG13 trials

Sponsors

Universitair Medisch Centrum Utrecht, Hospital Universitari Vall d'Hebron Research Institute, Hadassah Medical Organization, Geha Mental Health Center, Universitätsklinikum Hamburg-Eppendorf

Conditions

Abdominal PainAnxiety DisordersBone Mineral Density Quantitative Trait Locus 7Cerebral StrokeCognitive Performance in Major DepressionDecision MakingDementiaDepression

Phase 2

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

RecruitingNCT05133804

University of HaifaPosttraumatic Stress Disorder

Start: 2022-06-01End: 2025-12-01Target: 53Updated: 2025-03-27

Phase 3

Antidepressants and Bone Mineral Density

CompletedNCT02179268

Guiyang Medical UniversityBone Mineral Density Quantitative Trait Locus 7

Start: 2012-03-31End: 2014-04-30Updated: 2014-07-01

Pharmacovigilance in Gerontopsychiatric Patients

TerminatedNCT02374567

Hannover Medical SchoolAnxiety Disorders, Dementia, Depression +2

Start: 2015-01-31End: 2017-06-28Updated: 2018-02-28

A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for major depressive disorder compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

RecruitingCTIS2023-506617-21-00

Universitair Medisch Centrum UtrechtMajor depressive disorder

Start: 2024-08-29Target: 360Updated: 2025-04-17

Phase 4

Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

Hospital Universitari Vall d'Hebron Research InstituteAbdominal Pain, Major Depression, Pain

Start: 2005-09-30End: 2011-04-30Target: 42Updated: 2010-05-27

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Geha Mental Health CenterDepression

Start: 2005-01-31Target: 60Updated: 2007-01-25

Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation

CompletedNCT00853866

Universitätsklinikum Hamburg-EppendorfCerebral Stroke

Start: 2009-01-31End: 2010-06-30Updated: 2024-12-10

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Fundació Sant Joan de DéuSchizophrenia

Start: 2008-11-30Target: 249Updated: 2011-02-21

Unknown Phase

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

CompletedNCT00421369

Hadassah Medical OrganizationMajor Depressive Disorder

Start: 2007-09-30End: 2011-08-31Updated: 2013-03-22

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

CompletedNCT00993876

Zentrum für Integrative PsychiatrieCognitive Performance in Major Depression

Start: 2005-08-31End: 2008-08-31Updated: 2009-10-14

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

CompletedNCT03957174

University of OxfordHealthy

Start: 2019-06-01End: 2020-06-01Updated: 2020-06-16

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

CompletedNCT04371146

University of ZurichHealthy

Start: 2019-07-03End: 2020-02-13Updated: 2020-05-01

Studying the Role of Brain Molecules for Decision Making

CompletedNCT04384562

University of ZurichDecision Making, Healthy

Start: 2020-12-17End: 2021-12-13Updated: 2024-05-08

Related Papers

Double-Blind, Placebo-Controlled Study of the Efficacy of Reboxetine and Citalopram as Adjuncts to Atypical Antipsychotics for Negative Symptoms of Schizophrenia

The Journal of Clinical Psychiatry2014-06-1520 citations